Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole

Completed · Phase 4

Conditions studied: Short Stature

In brief

The purpose of the study is to determine if there are differences in the final height or hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now routinely used to increase stature: Anastrozole and Letrozole. It also should determine if there are differences in the side effect profiles of the two drugs to be used.

Key facts

Study ID

NCT02137538

Run by

Stanford University

People needed

79

Starts

2009-11-18

Expected to finish

2018-06-05

Last updated by the study team

2021-07-15

Who can join

Age: 10 and older, up to 17. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Current height less than 5th percentile AND/OR
• Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
• Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl

You may not qualify if…

• Bone age reading more than 14.0 years
• Follicle stimulating hormone > 20 IU/L

Where it is running

• Lucile Packard Children's Hospital — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.